Limits...
Open-label, Randomized Crossover Study Between Telmisartan and Valsartan on Improving Insulin Resistance and Adipocytokines in Nondiabetic Patients with Mild Hypertension.

Ohbayashi H, Minatoguchi S, Aoyama T, Fujiwara H - J Rural Med (2010)

Bottom Line: Serum adiponectin did not increase in either treatment group.Serum hsCRP levels also significantly decreased in the high hsCRP subjects (>/=0.1) of both treatment groups (p=0.044 and p=0.015, respectively).Telmisartan significantly improved insulin resistance, possibly through the effect on PPAR-gamma, while both telmisartan and valsartan significantly decreased serum leptin levels in female groups and hsCRP in both genders, suggesting no significantly different effects on adipocytokines by either drug in nondiabetic patients with mild hypertension.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, JA Gifu Tohno-Kousei Hospital, Japan ; Second Department of Internal Medicine, Gifu University School of Medicine, Japan.

ABSTRACT

Objective: The comparative effect of telmisartan and valsartan upon insulin resistance and adipocytokines in nondiabetic patients with mild hypertension is unclear.

Methods: Fifty nondiabetic patients with untreated mild hypertension were randomly assigned to telmisartan (40 mg/day) and valsartan (80 mg/day) groups and were switched in a crossover manner at 3-month intervals. Serum leptin, adiponectin, hsCRP and the HOMA-R were measured before and at 3 months during each treatment period.

Results: The HOMA-R significantly improved over the 3 months in the high insulin resistance group (HOMA-R>/=2.5) during the telmisartan treatment period (p=0.042), but not during the valsartan period. Both telmisartan and valsartan significantly decreased serum leptin levels in each female group during each treatment period (p<0.001 and p<0.001, respectively), but not in the male groups. Serum adiponectin did not increase in either treatment group. Serum hsCRP levels also significantly decreased in the high hsCRP subjects (>/=0.1) of both treatment groups (p=0.044 and p=0.015, respectively).

Conclusions: Telmisartan significantly improved insulin resistance, possibly through the effect on PPAR-gamma, while both telmisartan and valsartan significantly decreased serum leptin levels in female groups and hsCRP in both genders, suggesting no significantly different effects on adipocytokines by either drug in nondiabetic patients with mild hypertension.

No MeSH data available.


Related in: MedlinePlus

Time-course changes in (A) the HOMA-R indexes, (B) serum leptin levels, (C) serumadiponectin levels and (D) serum hsCRP levels over the study period. Statisticalsignificance: *p/3<0.05 and **p/3<0.01 compared with the values at the startof the study.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4309358&req=5

fig_003: Time-course changes in (A) the HOMA-R indexes, (B) serum leptin levels, (C) serumadiponectin levels and (D) serum hsCRP levels over the study period. Statisticalsignificance: *p/3<0.05 and **p/3<0.01 compared with the values at the startof the study.

Mentions: During the treatment period with telmisartan, although the changes were not significant,the values of IRI decreased from 9.4 ± 8.6 to 8.1 ± 13.4 (IU/L). The changes in the IRItended to be remarkable in the high insulin resistance group (HOMA-R >/= 2.5), from17.2 ± 10.9 to 13.1 ± 12.6 (IU/L; p=0.412). On the other hand, we found no change in theIRI during valsartan treatment period, from 8.5 ± 3.9 to 8.6 ± 4.7 (IU/L). We found nosignificant changes in the FBS values in both the telmisartan and valsartan treatmentperiods. As shown in Figure 3 (A)Figure 3.


Open-label, Randomized Crossover Study Between Telmisartan and Valsartan on Improving Insulin Resistance and Adipocytokines in Nondiabetic Patients with Mild Hypertension.

Ohbayashi H, Minatoguchi S, Aoyama T, Fujiwara H - J Rural Med (2010)

Time-course changes in (A) the HOMA-R indexes, (B) serum leptin levels, (C) serumadiponectin levels and (D) serum hsCRP levels over the study period. Statisticalsignificance: *p/3<0.05 and **p/3<0.01 compared with the values at the startof the study.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4309358&req=5

fig_003: Time-course changes in (A) the HOMA-R indexes, (B) serum leptin levels, (C) serumadiponectin levels and (D) serum hsCRP levels over the study period. Statisticalsignificance: *p/3<0.05 and **p/3<0.01 compared with the values at the startof the study.
Mentions: During the treatment period with telmisartan, although the changes were not significant,the values of IRI decreased from 9.4 ± 8.6 to 8.1 ± 13.4 (IU/L). The changes in the IRItended to be remarkable in the high insulin resistance group (HOMA-R >/= 2.5), from17.2 ± 10.9 to 13.1 ± 12.6 (IU/L; p=0.412). On the other hand, we found no change in theIRI during valsartan treatment period, from 8.5 ± 3.9 to 8.6 ± 4.7 (IU/L). We found nosignificant changes in the FBS values in both the telmisartan and valsartan treatmentperiods. As shown in Figure 3 (A)Figure 3.

Bottom Line: Serum adiponectin did not increase in either treatment group.Serum hsCRP levels also significantly decreased in the high hsCRP subjects (>/=0.1) of both treatment groups (p=0.044 and p=0.015, respectively).Telmisartan significantly improved insulin resistance, possibly through the effect on PPAR-gamma, while both telmisartan and valsartan significantly decreased serum leptin levels in female groups and hsCRP in both genders, suggesting no significantly different effects on adipocytokines by either drug in nondiabetic patients with mild hypertension.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, JA Gifu Tohno-Kousei Hospital, Japan ; Second Department of Internal Medicine, Gifu University School of Medicine, Japan.

ABSTRACT

Objective: The comparative effect of telmisartan and valsartan upon insulin resistance and adipocytokines in nondiabetic patients with mild hypertension is unclear.

Methods: Fifty nondiabetic patients with untreated mild hypertension were randomly assigned to telmisartan (40 mg/day) and valsartan (80 mg/day) groups and were switched in a crossover manner at 3-month intervals. Serum leptin, adiponectin, hsCRP and the HOMA-R were measured before and at 3 months during each treatment period.

Results: The HOMA-R significantly improved over the 3 months in the high insulin resistance group (HOMA-R>/=2.5) during the telmisartan treatment period (p=0.042), but not during the valsartan period. Both telmisartan and valsartan significantly decreased serum leptin levels in each female group during each treatment period (p<0.001 and p<0.001, respectively), but not in the male groups. Serum adiponectin did not increase in either treatment group. Serum hsCRP levels also significantly decreased in the high hsCRP subjects (>/=0.1) of both treatment groups (p=0.044 and p=0.015, respectively).

Conclusions: Telmisartan significantly improved insulin resistance, possibly through the effect on PPAR-gamma, while both telmisartan and valsartan significantly decreased serum leptin levels in female groups and hsCRP in both genders, suggesting no significantly different effects on adipocytokines by either drug in nondiabetic patients with mild hypertension.

No MeSH data available.


Related in: MedlinePlus